Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

PubWeight™: 0.80^‹?›

🔗 View Article (PMID 26308766)

Published in Cancer on August 26, 2015

Authors

Richard H Ko¹^,2, Tamekia L Jones³, David Radvinsky⁴, Nathan Robison¹^,2, Paul S Gaynon¹^,2, Eduard H Panosyan⁵, Ioannis A Avramis¹, Vassilios I Avramis¹^,2, Joan Rubin⁶, Lawrence J Ettinger⁷, Nita L Seibel⁸, Girish Dhall¹^,2

Author Affiliations

1: Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
2: Keck School of Medicine, University of Southern California, Los Angeles, California.
3: Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
4: State University of New York of New York Downstate Medical Center, Brooklyn New York.
5: Division of Pediatric Hematology and Oncology, Harbor-University of California Los Angeles Medical Center, Torrance, California.
6: Department of Pediatrics, St. Peter's University Hospital, New Brunswick, New Jersey.
7: Children's Oncology Group, Monrovia, California.
8: Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.

Articles citing this ↘

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother (2016) 0.75

Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase? Pediatr Blood Cancer (2016) 0.75

Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res (2017) 0.75

Articles cited by this ↗

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2007) 3.79

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood (2002) 2.76

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood (2002) 2.05

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.91

Inhibition of leukemias in man by L-asparaginase. Cancer Res (1967) 1.88

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol (2004) 1.80

L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA (1967) 1.78

Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist (2007) 1.29

The toxicity of Escherichia coli L-asparaginase. Cancer Res (1969) 1.25

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia (2003) 1.18

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer (1966) 1.15

Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy (2003) 1.12

Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma (2010) 1.05

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol (2001) 1.02

The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med (2009) 1.02

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol (2013) 0.97

ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods (2000) 0.94

Immunological responses to L-asparaginase. J Clin Invest (1971) 0.94

Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer (2006) 0.80

The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial. Blood Cancer J (2014) 0.79

Articles by these authors ⇆

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Pediatr Blood Cancer (2015) 0.78